TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc.

TLSI·NASDAQ

$3.29

+3.0%
HealthcareMedical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

At a Glance

Live Snapshot
Market Cap$124.72M
EPS-1.8400
P/E Ratio-1.79
Earnings Date08/11/2026

tlsi

Net Debt

Last Annual Value

14.00M

3-Year CAGR

57%

5-Year CAGR

-18%

10-Year CAGR

-9%

TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. Competitors Analysis of Net Debt

TLSI · NASDAQ
CompanyNet Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
14.00M
N/AN/AN/A 
MXCT logo
MaxCyte, Inc.
NASDAQ:MXCT
-2.12M
N/AN/AN/A
-76.96M
N/AN/AN/A
-51.19M
N/AN/AN/A
HYPR logo
Hyperfine, Inc.
NASDAQ:HYPR
-34.77M
N/AN/AN/A
35.80M
20.8%N/AN/A
3.84M
N/AN/AN/A
LNSR logo
LENSAR, Inc.
NASDAQ:LNSR
-10.24M
N/AN/AN/A
-29.00M
N/AN/AN/A
56.17M
171.8%N/A33.6%
279.33M
37.8%58.8%N/A
TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. Fair Value Envelope

TLSI · NASDAQ

Our analysis suggests that TLSI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.29, this represents a potential HIDDEN relative to our calculated worth for TriSalus Life Sciences, Inc..

Intrinsic Value
Current Price: $3.29